May 14, 2013 | finance.yahoo.com
– Tarceva is the First Personalized Medicine Approved for the Initial Treatment of People with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer in the United States – SOUTH SAN FRANCISCO, Calif. & NORTHBROOK,...
Read more...
Tarceva EGFR NSCLC mutation lung EURTAC Astellas Tarceva-treated cobas Genentech patient cancer
May 14, 2013 | dailyfinance.com
Filed under: Investing FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test for Specific Type of Lung Cancer - Tarceva is the First Personalized Medicine Approved for the Initial Treatment of People with EGFR...
Read more...
Tarceva EGFR NSCLC Astellas mutation Genentech Cobas Erlotinib patient EURTAC lung cancer chemotherapy
May 15, 2013 | istockanalyst.com
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Astellas Pharma US, Inc. (“Astellas”), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced that the U.S. Food and Drug...
Read more...
Tarceva EGFR NSCLC mutation EURTAC lung Astellas Tarceva-treated cobas Genentech patient cancer
May 15, 2013 | finanznachrichten.de
SOUTH SAN FRANCISCO (dpa-AFX) - Genentech, a member of the Roche Group (RHHBY, ROG) Tuesday said it has received approval from the U.S. Food and Drug Administration, or FDA, for Tarceva tablets used in initial treatment of...
Read more...
Tarceva EGFR Genentech mutation FDA U.S approval tablet EURTAC chemotherapy test NSCLC
May 15, 2013 | vegas24seven.com
Cancer Treatment Centers of America Appoints Dr. Glen J. Weiss as Director of Clinical Research Cancer Treatment Centers of America® (CTCA) announced today that Glen J. Weiss, MD, has been named the Director of Clinical...
Read more...
Weiss CTCA Dr. clinical cancer treatment Glen patient J. research America
May 15, 2013 | ayurvedicnaturalcure.com
Being the second most prevalent cancerous strain, lung cancer has noted adverse effects on the body and mind. The treatment associated with this can get expensive and highly intricate as the clause of side effect needs to be...
Read more...
Shubham Das cancer lung natural effect cure effective cell inhibit noted immunity usana.family.my prevent vitamin C curing MGN-3
May 14, 2013 | finanznachrichten.de
– Tarceva is the First Personalized Medicine Approved for the Initial Treatment of People with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer in the United States – Genentech, a member of the Roche Group (SIX: RO,...
Read more...
Tarceva EGFR NSCLC mutation lung EURTAC Astellas Tarceva-treated cobas Genentech patient cancer
May 15, 2013 | irishexaminer.com
Wednesday, May 15, 2013 Today, inspirational teenager Dónal Walsh will be buried. This is an essay he wrote about how he dealt with his two crushing cancer diagnoses THE first time they told me I was at home, I was on the phone...
Read more...
chemo Dónal tube pain ward Walsh essay friend catheter crutch cry mom again OK
May 15, 2013 | yahoo.com
Marketwired] - IsoRay, Inc. , a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer, prostate cancer and gynecologic ...
Read more...
IsoRay cancer Cesium-131 Cs-131 prostate brachytherapy quarter Cesium
May 14, 2013 | bloomberg.com
Roche Holding AG (ROG) , the world’s biggest maker of cancer drugs, won U.S. approval to sell a gene mutation test that can help doctors pinpoint patients’ likelihood to respond to a popular treatment for lung cancer. The...
Read more...
Anna Edney lung Roche cancer FDA mutation EGFR approval test Tarceva gene Qiagen BRCA1 Boehringer non-small drug-and-diagnostic
May 15, 2013 | marketwire.com
28% Increase in Third Quarter Revenues Over Second Quarter RICHLAND, WA--(Marketwired - May 15, 2013) - IsoRay , Inc. , a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for...
Read more...
IsoRay cancer Cesium-131 Cs-131 prostate brachytherapy quarter Cesium
May 15, 2013 | addictinginfo.org
Even regular marijuana smokers will be somewhat surprised by these results. Read more → The post Study Demonstrates Smoking Pot Doesn’t Cause Lung Cancer, No Matter The Frequency Or Amount appeared first on Addicting Info .
Read more...
Justin Acuff marijuana Tashkin lung smoking cancer study smoker demonstrate matter cancer-causing cause
May 15, 2013 | macreportmedia.com
28% Increase in Third Quarter Revenues Over Second Quarter RICHLAND, WA-- May 15, 2013 - ), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer,...
Read more...
IsoRay cancer Cs-131 prostate quarter Cesium lung gyn brachytherapy
May 14, 2013 | medpagetoday.com
WASHINGTON (MedPage Today) -- The FDA has approved a companion EGFR mutation test for use with the targeted cancer drug erlotinib (Tarceva) to help guide decision making in non-small cell lung cancer.
Read more...
mutation lung FDA EGFR cancer NSCLC cobas erlotinib test approve exon Tarceva non-small first-line
May 15, 2013 | wvgazette.com
CHARLESTON, W.Va. -- There are five basic categories of psychoactive substances: Stimulants, such as nicotine, cocaine and caffeine; depressants, including sedatives, anxiety reducing drugs, alcohol, sleeping pills and opioid...
Read more...
marijuana Maddox smoke pot smoking psychoactive lung cannabis drug carcinogenic nicotine
May 15, 2013 | prweb.com
The Lung Cancer Asbestos Victims Center is aggressively attempting to make certain every diagnosed victim of mesothelioma, or victim of lung cancer who had long term exposure to asbestos in the workplace calls them at...
Read more...
asbestos mesothelioma victim lung cancer exposure Victims
May 15, 2013 | zimbabwestar.com
Genentech Inc. won regulatory approval Tuesday to use its cancer drug Tarceva and a companion diagnostic for non-small cell lung cancer patients with a rare gene mutation. It is the first companion diagnostic approved by the...
Read more...
Genentech diagnostic lung FDA cancer Roche drug OK test Molecular mutation non-small
May 15, 2013 | auntminnie.com
May 15, 2013 -- In a comparison of hybrid imaging modalities, simultaneous whole-body PET/MRI is more accurate than retrospectively fused PET and MR images in abdominal organs and better than PET/CT in the urinary bladder,...
Read more...
PET MRI STIR alignment ± CT simultaneous mm image protocol
May 14, 2013 | dailylocal.com
Vanguard Tuesday announced the introduction of Vanguard Emerging Markets Government Bond Index Fund, the company’s first international fixed income offering available to U.S. investors. The fund is now accepting investments...
Read more...
vanguard lung Tarceva patient bushel fund cancer portfolio cobas Roche mutation diagnostics acre drug non-small genetic FDA Genentech test approve vanguard.com
May 14, 2013 | health.yahoo.com
U.S. health regulators on Tuesday approved a test developed by Roche for a specific gene mutation present in about 10 percent of non-small cell lung cancers, and said the company's drug Tarceva could be used as an initial...
Read more...
mutation Roche lung diagnostic gene cancer FDA EGFR approve Tarceva non-small patient
May 15, 2013 | jamaicantimes.com
Genentech Inc. won regulatory approval Tuesday to use its cancer drug Tarceva and a companion diagnostic for non-small cell lung cancer patients with a rare gene mutation. It is the first companion diagnostic approved by the...
Read more...
Genentech diagnostic lung FDA cancer Roche drug OK test Molecular mutation non-small
May 15, 2013 | middleeaststar.com
Genentech Inc. won regulatory approval Tuesday to use its cancer drug Tarceva and a companion diagnostic for non-small cell lung cancer patients with a rare gene mutation. It is the first companion diagnostic approved by the...
Read more...
Genentech diagnostic lung FDA cancer Roche drug OK test Molecular mutation non-small
May 14, 2013 | finance.yahoo.com
Anti-Notch2/3 (OMP-59R5) Phase 1b/2 PINNACLE Trial in SCLC Initiated Enrollment of First Patient to PINNACLE Triggers Milestone Payment from GSK Anti-Notch2/3 (OMP-59R5) Phase 1b/2 ALPINE Trial in Pancreatic Cancer Amended to...
Read more...
OncoMed Anti-Notch2 OMP-59R5 1b cell CSCs cancer trial Phase anti-Notch stem etoposide patient clinical
May 14, 2013 | fortmilltimes.com
OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced clinical progress with its Anti-Notch2/3 (OMP-59R5) product...
Read more...
OncoMed Anti-Notch2 OMP-59R5 1b cell CSCs cancer trial Phase anti-Notch stem etoposide patient clinical
May 14, 2013 | fda.gov
The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test, a companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved companion diagnostic that detects epidermal...
Read more...
Tarceva EGFR lung mutation NSCLC cobas companion FDA diagnostic gene approve cancer detect patient type
May 14, 2013 | checkorphan.org
Zeltia has announced that its subsidiary PharmaMar has completed a Phase Ib trial with PM01183 in combination with Doxorubicin. The results of the trial will be presented at an upcoming oncology conferenceThe combination...
Read more...
PharmaMar PM01183 Zeltia Doxorubicin Ib trial marine-based cancer combination endometrial antitumour
May 14, 2013 | prnewswire.com
WALTHAM, Mass., May 14, 2013 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on developing novel combination epigenetic strategies to treat cancers that have become resistant to standard...
Read more...
entinostat Syndax aromatase cancer breast inhibitor Clinical estrogen ENCORE Pharmaceuticals
May 14, 2013 | pr-express.com
lt style type text css gt lt cke_protected C lt page margin 0 79in P margin bottom 0 08in A link color 0000ff gt gt lt style gt Lung cancer is one of the most dangerous forms of cancer that anyone can suffer from It is true...
Read more...
cancer treatment lung patient type different condition determine
May 14, 2013 | thelancet.com
We found a high level of evidence that DFS is a valid surrogate endpoint for overall survival in studies of adjuvant chemotherapy involving patients with non-small-cell lung cancers, and PFS in those of chemotherapy and...
Read more...
radiotherapy endpoint chemotherapy survival ρ2 trial 0·61 0·71 correlation 0·83 0·87 overall CI R2 0·98 0·85 0·92 0·95 0·77 lung surrogate PFS DFS adjuvant
May 14, 2013 | myhotarticles.net
Lung cancer is one of the most dangerous forms of cancer that anyone can suffer from. It is true that there are many different types of cancers, and the options for cancer treatmentsare also many. However, these treatment...
Read more...
Sentryfence cancer treatment lung patient type different condition determine option